Newsroom | 63992 results

Sorted by: Latest

Research
-

Anthem Establishes Coverage of C2N Diagnostics’ PrecivityAD2® Blood Test for Alzheimer's Disease Evaluation

ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, announced that beginning October 1, 2026, eligible Anthem® Blue Cross® and Blue Shield® members will be the first in the United States to receive insurance coverage under a medical policy for the PrecivityAD2® blood test. This policy expands patient access to an innovative blood-based diagnostic test that helps health care professionals evaluate adults exp...
-

Universal Orthodontic Lab Appoints Dr. Ryo Hamanaka, DDS, PhD as Chief Clinical Officer and Head of Experimental Applications Group

NORWALK, Calif.--(BUSINESS WIRE)--Universal Orthodontic Lab Appoints Dr. Ryo Hamanaka, DDS, PhD as Chief Clinical Officer and Head of Experimental Applications Group....
-

Sumitomo Biorational Company Names Remy Lyczko As President, AgroSolutions Division

LIBERTYVILLE, Ill.--(BUSINESS WIRE)--Sumitomo Biorational Company LLC today announced the appointment of Remy Lyczko as President of its AgroSolutions Division (ASD), effective July 1, 2026. In this role, Lyczko will lead the division responsible for developing innovative biorational and botanical technologies that help growers improve productivity while advancing more sustainable agricultural systems. Under his leadership, the division will continue to expand solutions that support modern farm...
-

OpenEvidence and NewYork-Presbyterian, Columbia University and Weill Cornell Medicine Expand Clinical AI Tools Across New York City and Westchester

MIAMI & NEW YORK--(BUSINESS WIRE)--OpenEvidence, a medical AI and clinical decision support tool for U.S. clinicians, today announced a collaboration with NewYork-Presbyterian and its affiliated medical schools, Columbia University Vagelos College of Physicians and Surgeons and Weill Cornell Medicine, to deploy OpenEvidence across all hospitals and care sites throughout the Greater New York region. This enterprise-scale collaboration will place trusted, evidence-based clinical AI in the hands o...
-

Maryland Tech Council Announces New Board of Directors

ROCKVILLE, Md.--(BUSINESS WIRE)--The Maryland Tech Council (MTC), the largest technology and life sciences trade association in the state, today announced the election of new members to its Board of Directors. Bringing decades of expertise across technology, life sciences, and related industries, the directors will help guide MTC’s strategy and planning for the 2-year term. "We are excited to collaborate with this dynamic group of new board members," said Kelly Schulz, CEO of the Maryland Tech...
-

The 30-Second Test for Ear Infections That Pays for Itself: New Urgent Care Study Uses Intellivisit Data to Validate the Case for Tympanometry

NASHVILLE, Tenn.--(BUSINESS WIRE)--Most doctors use the same tool to assess children’s ears as when their caregivers visited the pediatrician decades ago. The otoscope, the tool clinicians squint through when examining the ears, has remained essentially unchanged for more than 50 years. A new study in the Journal of Urgent Care Medicine (JUCM), built on 140,894 real-world Intellivisit encounters, examined a more accurate and less uncomfortable tool for ear exams — the tympanometer. The research...
-

Arialys Therapeutics Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of Anti-NMDA Receptor Encephalitis

LA JOLLA, Calif.--(BUSINESS WIRE)--Arialys Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of ANRE...
-

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven bios...
-

Esri and Global Partners Release HydroSHEDS v2 for the Americas

REDLANDS, Calif.--(BUSINESS WIRE)--Esri has made HydroSHEDS v2 publicly available for the first time. Confluvio Consulting led the development of the HydroSHEDS v2 foundational dataset in partnership with the German Aerospace Center (DLR) and Esri, whose geographic information system (GIS) technology will provide users with the data. A major innovation in global hydrographic capabilities, this hydrographic framework is the result of a collaboration initiated by World Wildlife Fund (WWF) and McG...
-

Takara Bio USA, Inc. Announces the Retirement of Carol Lou, Appoints Andrew Farmer as President and CEO

SAN JOSE, Calif.--(BUSINESS WIRE)--President & CEO of Takara Bio USA Carol Lou announces she is retiring after 20 years of service, with Andrew Farmer as her successor....